# Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

> **NCT04952597** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 126 (actual)

## Conditions studied

- Limited Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Ociperlimab
- **DRUG:** Tislelizumab
- **DRUG:** Concurrent Chemoradiotherapy

## Key facts

- **NCT ID:** NCT04952597
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-15
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952597, "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04952597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*